Format

Send to

Choose Destination
Breast Cancer Res Treat. 2017 Oct;165(3):573-583. doi: 10.1007/s10549-017-4358-6. Epub 2017 Jun 29.

Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.

Author information

1
West German Study Group, Ludwig-Weber-Str. 15, 41061, Moenchengladbach, Germany.
2
Ev. Hospital Bethesda, Breast Center Niederrhein, Ludwig-Weber-Str. 15, 41061, Moenchengladbach, Germany.
3
West German Study Group, Ludwig-Weber-Str. 15, 41061, Moenchengladbach, Germany. oleg.gluz@wsg-online.com.
4
Ev. Hospital Bethesda, Breast Center Niederrhein, Ludwig-Weber-Str. 15, 41061, Moenchengladbach, Germany. oleg.gluz@wsg-online.com.
5
Institute of Pathology, Medical School Hannover, Carl-Neuberg-Str. 1., 30625, Hannover, Germany.
6
Department of Oncology, Clinics Mutterhaus der Borromäerinnen, Feldstraße 16, 54290, Trier, Germany.
7
Department of Gynecology and Obstetrics, Breast Center, University Clinics Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
8
Department of Gynecology and Obstetrics, Evangelical Hospital, Ferrenbergstraße 24, 51465, Bergisch Gladbach, Germany.
9
Department of Gynecology and Obstetrics, University Clinics Essen, Hufelandstraße 55, 45147, Essen, Germany.
10
Clinics Essen-Mitte, Breast Centre, Henricistraße 92, 45136, Essen, Germany.
11
Department of Gynecology and Obstetrics, Clinics Suedstadt, Südring 81, 18059, Rostock, Germany.
12
Johanniter Clinics Stendal, Breast Center Altmark, Bahnhofstraße 24 - 26, 39576, Stendal, Germany.
13
Department of Gynecology, Dr. Horst-Schmidt Clinics, Ludwig-Erhard-Straße 100, 65199, Wiesbaden, Germany.
14
Klinikum ChemnitzFlemmingstraße 2, 09116, Chemnitz, Germany.
15
Oncological Practice, Teutoburger Str. 60 33604, Bielefeld, Germany.
16
Breast Centre Ostbayern, Perlasberger Str. 41, 94469, Deggendorf, Germany.
17
Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein Campus Luebeck, Ratzeburger Allee 160, 23562, Luebeck, Germany.
18
Genomic Health, Inc., Redwood City, CA, USA.
19
Department of Gynecology and Obstetrics, Breast Center, University of Munich (LMU) and CCCLMU, Munich, Germany.

Abstract

BACKGROUND:

The prospective phase 3 PlanB trial used the Oncotype DX® Recurrence Score® (RS) to define a genomically low-risk subset of clinically high-risk pN0-1 early breast cancer (EBC) patients for treatment with adjuvant endocrine therapy (ET) alone. Here, we report five-year data evaluating the prognostic value of RS, Ki-67, and other traditional clinicopathological parameters.

METHODS:

A central tumour bank was prospectively established within PlanB. Following an early amendment, hormone receptor (HR)+ , pN0-1 RS ≤ 11 patients were recommended to omit chemotherapy. Patients with RS ≥ 12, pN2-3, or HR-negative/HER2-negative disease were randomised to anthracycline-containing or anthracycline-free chemotherapy. Primary endpoint: disease-free survival (DFS). PlanB Clinicaltrials.gov identifier: NCT01049425.

FINDINGS:

From 2009 to 2011, PlanB enrolled 3198 patients (central tumour bank, n = 3073) with the median age of 56 years, 41.1% pN+, and 32.5% grade 3 EBC. Chemotherapy was omitted in 348/404 (86.1%) eligible RS ≤ 11 patients. After 55 months of median follow-up, five-year DFS in ET-treated RS ≤ 11 patients was 94% (in both pN0 and pN1) versus 94% (RS 12-25) and 84% (RS > 25) in chemotherapy-treated patients (p < 0.001); five-year overall survival (OS) was 99 versus 97% and 93%, respectively (p < 0.001). Nodal status, central/local grade, tumour size, continuous Ki-67, progesterone receptor (PR), IHC4, and RS were univariate prognostic factors for DFS. In a multivariate analysis including all univariate prognostic markers, only pN2-3, central and local grade 3, tumour size >2 cm, and RS, but not IHC4 or Ki-67 were independent adverse factors. If RS was excluded, IHC4 or both Ki-67 and PR entered the model. The impact of RS was particularly pronounced in patients with intermediate Ki-67 (>10%, <40%) tumours.

INTERPRETATION:

The excellent five-year outcomes in clinically high-risk, genomically low-risk (RS ≤ 11) pN0-1 patients without adjuvant chemotherapy support using RS with standardised pathology for treatment decisions in HR+ HER2-negative EBC. Ki-67 has the potential to support patient selection for genomic testing.

KEYWORDS:

Breast cancer; Genomic signature; IHC4; Ki-67; Oncotype DX

PMID:
28664507
PMCID:
PMC6336763
DOI:
10.1007/s10549-017-4358-6
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center